Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Gynecol Obstet Invest ; 79(1): 19-24, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25413174

RESUMO

BACKGROUND/AIMS: The aim of this prospective study was to determine ionized and total magnesium (Mg) levels in pregnant subjects with and without gestational diabetes mellitus (GDM). METHODS: Eighty-five women, 26-28 weeks pregnant, were recruited for routine oral glucose tolerance tests (OGTT); 45 had normal OGTT results and 40 were diagnosed with GDM. Electrolyte levels, including ionized and total Mg, were analyzed. RESULTS: Gestational age and BMI were similar between the two groups (p = 0.800, p = 0.025). Multivitamin use was higher in the control group (p = 0.036). Fasting blood glucose was higher in the GDM group (p < 0.001). The median total Mg levels were 1.9 mg/dl (range 1.6-2.2) in the control group and 1.8 mg/dl (range 1.2-2.1) in the GDM group (p < 0.001). The median ionized Mg levels were 0.5 mmol/l (range 0.4-0.6) in the control group and 0.4 mmol/l (range 0.4-0.5) in the GDM group (p < 0.001). CONCLUSION: Our study revealed a relationship between low total and ionized Mg levels and GDM, as in type 2 diabetes mellitus (DM). The literature regarding type 2 DM and our findings suggest that Mg is the key ion in the pathophysiology of GDM. Low-dose Mg supplementation was not related to GDM; however, pharmacological doses in the various stages of pregnancy could be beneficial and should be investigated.


Assuntos
Diabetes Gestacional/sangue , Magnésio/sangue , Adulto , Glicemia/análise , Índice de Massa Corporal , Cálcio/sangue , Estudos Transversais , Diabetes Gestacional/etiologia , Suplementos Nutricionais , Jejum , Feminino , Idade Gestacional , Teste de Tolerância a Glucose , Humanos , Magnésio/administração & dosagem , Gravidez , Estudos Prospectivos
2.
Arch Gynecol Obstet ; 292(1): 209-16, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25524539

RESUMO

PURPOSE: The aim of this study was to test if melatonin causes regression of endometriotic implants and whether it influences implant levels of superoxide dismutase (SOD), malondialdehyde (MDA), vascular endothelial growth factor (VEGF), tissue inhibitor of metalloproteinase (TIMP)-2 and matrix metalloproteinase (MMP)-9 in rats. METHODS: Endometriotic implants were introduced surgically to 20 female Wistar albino rats, which were either treated with melatonin via intraperitoneal injection for four weeks (melatonin group, n = 10) or with saline (control group, n = 10) after a second-look laparotomies. The main outcome measures included volume (mm(3)) and weight (mg) of explants and tissue levels of SOD, MDA, VEGF, TIMP-2 and MMP-9. RESULTS: Before and after treatment implant volumes of the melatonin group were decreased significantly (P < 0.01) while there was no significant difference between the pretreatment and posttreatment implant volumes of the control group. Moreover, weight (P < 0.05) and histologic score (P < 0.05) of implants of the melatonin-treated rats were significantly lower than controls. Activity of SOD and TIMP-2 staining in melatonin group was significantly higher (both P < 0.01) while there were significant reductions in implant levels of VEGF and MMP-9 in melatonin group (both P < 0.01) than controls. CONCLUSIONS: Melatonin induces the regression of endometriotic implants in rats by modulating implant levels of SOD, MDA, VEGF, MMP-9 and TIMP-2.


Assuntos
Antioxidantes/metabolismo , Endometriose/tratamento farmacológico , Metaloproteinases da Matriz/metabolismo , Melatonina/farmacologia , Animais , Antioxidantes/administração & dosagem , Antioxidantes/farmacologia , Modelos Animais de Doenças , Endometriose/patologia , Feminino , Injeções Intraperitoneais , Malondialdeído/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Melatonina/administração & dosagem , Ratos , Ratos Wistar , Superóxido Dismutase/metabolismo , Inibidor Tecidual de Metaloproteinase-2/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo
3.
Gynecol Endocrinol ; 30(2): 135-40, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24308768

RESUMO

OBJECTIVE: In female cancer survivors, the accelerated loss of primordial follicles may lead to premature ovarian failure. We investigated the protective effects of bone marrow derived mesenchymal stem cells (BMMSC) and gonadotropin releasing hormone analogue (GnRHa) against chemotherapeutic-induced ovarian toxicity in a rat model. MATERIAL AND METHODS: Forty-eight Wistar albino female rats were divided into four groups. Group 1 was composed of rats that were given 200 mg/kg cyclophosphamide injection for each cycle (two cycles for each rat). Both cyclophosphamide and 0.4 µg GnRHa were administered to Group 2. Cyclophosphamide and 4 million/kg BMMSC were administered to Group 3. Cyclophosphamide, GnRHa, and BMMSC were administered to Group 4. Germ cell apoptosis, DNA fragmentation and primordial follicular count were investigated with Cleave Caspase-9 and TUNEL analysis. The presence of the SRY gene on the Y chromosome in the ovary of the recipient female rats was checked with PCR. RESULTS: Immunohistochemical staining (IHS) of Caspase-9 and TUNEL was higher in Group 1 than in Group 3 (p < 0.05). Similarly, Group 4 had higher values than Group 3 (p < 0.05). The presence of the SRY gene was detected in Groups 3 and 4 with the PCR analysis. The mean primordal follicle count was lowest in Group 1 and the mean primordial follicle counts were higher in Groups 2 and 3 than in Group 1. The difference between Group 1 and Group 4 was not significant. CONCLUSION: BMMSC therapy was found to be protective from germ cell apoptosis and DNA damage when it was used with chemotherapy regimens including alkylating agents.


Assuntos
Ciclofosfamida/administração & dosagem , Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais , Ovário/efeitos dos fármacos , Ovário/fisiologia , Insuficiência Ovariana Primária/prevenção & controle , Animais , Apoptose/efeitos dos fármacos , Fragmentação do DNA , Feminino , Folículo Ovariano/efeitos dos fármacos , Folículo Ovariano/fisiologia , Ratos , Ratos Wistar
4.
Gynecol Endocrinol ; 30(4): 320-4, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24460500

RESUMO

The aim of this study was to evaluate the time-dependent effect of progesterone-only contraceptives on the brain and to obtain an improved understanding of mood disorders experienced under this medication. A total of 66 Wistar albino rats were divided into three groups: etonogestrel (ENG) implant (group 1, n = 30); depot medroxyprogesterone acetate (MPA)-injectable (group 2, n = 30); and control (group 3, n = 6) groups. Groups 1 and 2 were each divided into five subgroups, which were examined every 10 d for up to 50 d after medication administration, to evaluate its time-dependent effect. There was no difference in terms of gamma-aminobutyric acid (GABA) and serotonin immunohistochemical staining in white and gray matter among the subgroups of group 1. In group 2, there was a significant decrease in serotonin receptor staining intensity in white and gray matter on day 50, when compared to the control group (p = 0.041). When the subgroups of group 2 were compared, there was a significant decrease in serotonin receptor staining intensity in white and gray matter on days 40 and 50 when compared to day 10. In conclusion, we showed that ENG and MPA have no effect on apoptosis and GABA-A receptors in the brain. We also showed that MPA has time-dependent effects on serotonin receptors, which may be a possible mechanism involved in mood disorders during long-term usage of injectable progesterone-only contraceptives.


Assuntos
Encéfalo/efeitos dos fármacos , Desogestrel/administração & dosagem , Acetato de Medroxiprogesterona/administração & dosagem , Receptores de Serotonina/metabolismo , Ácido gama-Aminobutírico/metabolismo , Animais , Apoptose/efeitos dos fármacos , Encéfalo/citologia , Encéfalo/metabolismo , Feminino , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Distribuição Aleatória , Ratos , Ratos Wistar , Estatísticas não Paramétricas
5.
J Assist Reprod Genet ; 31(8): 975-82, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24974357

RESUMO

PURPOSE: We evaluate the effect of stem cells to induce endometrial proliferation and angiogenesis on Asherman Syndrome (AS). METHODS: The experimental study was performed in stemcell research laboratory. Forty Wistar-Albino rats were divided according to groups. In group1 (n = 10) to establish the model; trichloroacetic acid was injected to right uterine horn. Two weeks later, intrauterine synechia was confirmed. In group2 (n = 10), 2 weeks later, 2 × 106 mesenchymal stem cells (MSC) were injected into right uterine horn followed by three intraperitoneal injections of MSCs. In group3 (n = 10), daily oral estrogen was initiated on the second week. In group4 (n = 10), MSC injections and oral estrogen was given together. The amount of fibrosis, vascularisation, inflammation and immunohistochemical staining with vascular endothelial growth factor (VEGF), proliferating cell nuclear antigen (PCNA) and Ki-67 were evaluated in the uterine tissues. RESULTS: In all treatment groups; fibrosis decreased but vascularisation and immunhistohemical stainings increased in the experimental side. The amount of fibrosis, vascularisation, Ki-67 and PCNA scores were similar between group2 and 3. In group4, comparing to group2, less fibrosis but more Ki-67, PCNA and VEGF staining was observed. CONCLUSION: Stem cells, when added to estrogen, are a highly effective alternative to induce regeneration of endometrium in Asherman Syndrome therapy.


Assuntos
Tecido Adiposo/citologia , Endométrio/citologia , Fibrose/prevenção & controle , Ginatresia/patologia , Inflamação/prevenção & controle , Células-Tronco Mesenquimais/citologia , Neovascularização Fisiológica , Tecido Adiposo/metabolismo , Animais , Biomarcadores/metabolismo , Diferenciação Celular , Células Cultivadas , Endométrio/metabolismo , Feminino , Fibrose/metabolismo , Fibrose/patologia , Ginatresia/metabolismo , Técnicas Imunoenzimáticas , Inflamação/metabolismo , Inflamação/patologia , Células-Tronco Mesenquimais/metabolismo , Ratos , Ratos Wistar
6.
Gynecol Endocrinol ; 28(6): 463-7, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22578029

RESUMO

Apoptosis is necessary for the balance between cell proliferation and loss. Thirty-six Wistar-Albino rats were subjected to investigate apoptotic effect of widely used implantable progestins on ovarian and uterine tissues. Rats were divided into 6 groups. In the first five groups, we applied etonogestrel (IMP) subcutaneous implants (n = 30). The rats in groups were sacrificed sequentially every 10 days after application. The rats in the last group (n = 6) were accepted as controls. Apoptotic index (AI) values and Caspase-3 immunoreactivities of ovaries and uterus were recorded. In IMP groups, AI and Hscore values in stroma and glandular epithelium of uterus, granulosa and teca-lutein cells of the ovary increased with the longer progesterone exposure. Increase in AI and Hscore values were more prominent after 30 days of exposure for teca-lutein cells of ovary. Progestins increased apoptosis in ovaries and uterus by the longer exposure. Apoptosis increased in ovaries by chronic progesterone exposure. The apoptotic effect of progestin on endometrium is clear but long-term systemic application may lead to alterations in ovarian physiology. We evaluated time dependent apoptotic effect of etonogestrel on reproductive physiology and discussed progestins effect from another point of view in this study.


Assuntos
Apoptose/efeitos dos fármacos , Caspase 3/metabolismo , Desogestrel/farmacologia , Ovário/efeitos dos fármacos , Útero/efeitos dos fármacos , Animais , Anticoncepcionais Femininos/farmacologia , Feminino , Indicadores Básicos de Saúde , Imuno-Histoquímica , Ovário/citologia , Ovário/fisiologia , Ratos , Ratos Wistar , Fatores de Tempo , Útero/citologia , Útero/fisiologia
7.
Clin Oral Implants Res ; 22(5): 546-51, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21121960

RESUMO

PURPOSE: The aim of this study was to evaluate the success rate of chemically modified and conventional sandblasted acid-etched surface (SLA) titanium implants in irradiated oral squamous cell carcinoma patients. MATERIAL AND METHODS: Twenty patients with a mean age of 61.1 years were treated with dental implants after ablative surgery and radio-chemotherapy of oral cancer. All patients were non-smokers. The placement of SLA and modSLA implants was performed bilaterally according to a split-mouth design. All 102 implants (50 SLA, 52 modSLA) placed showed an unloaded healing time of 6 weeks in the mandible and 10 weeks in the maxilla. Mean crestal bone changes using standardized orthopantomographies and clinical parameters like pocket depths, mPII and mBI were evaluated. RESULTS: Of 102 implants, 55 implants (27 SLA implants, 28 modSLA) were located in the maxilla and 47 implants (23 SLA, 24 modSLA) in the mandible. The average observation period was 14.4 months. The amount of bone loss at the implant shoulder of SLA implants was 0.4 mm mesial and 0.4 mm distal. The modSLA implants displayed a bone loss of mesial 0.3 mm and distal 0.3 mm. Two SLA implants were lost resulting in a success rate of 96%. The success rate of modSLA implants was 100%. CONCLUSION: Regarding the data found in this investigation, we can conclude that implants with chemically modified and conventional SLA titanium surface show high success rates in irradiated patients. SLA implants with or without a chemically modified surface regardless of the location can be restored with a high predictability of success at least in the short time range observed.


Assuntos
Condicionamento Ácido do Dente/métodos , Carcinoma de Células Escamosas/radioterapia , Corrosão Dentária/métodos , Implantes Dentários , Materiais Dentários/química , Neoplasias Mandibulares/radioterapia , Titânio/química , Idoso , Perda do Osso Alveolar/classificação , Implantação Dentária Endóssea/métodos , Planejamento de Prótese Dentária , Prótese Dentária Fixada por Implante , Falha de Restauração Dentária , Feminino , Humanos , Masculino , Mandíbula/diagnóstico por imagem , Mandíbula/efeitos da radiação , Mandíbula/cirurgia , Maxila/diagnóstico por imagem , Maxila/efeitos da radiação , Maxila/cirurgia , Pessoa de Meia-Idade , Terapia Neoadjuvante , Índice Periodontal , Bolsa Periodontal/classificação , Radiografia , Propriedades de Superfície , Resultado do Tratamento
8.
Gynecol Endocrinol ; 27(9): 622-9, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21105835

RESUMO

Our aim was to evaluate the optimal treatment strategy addressing cardiovascular risk in obese and nonobese patients with polycystic ovary syndrome (PCOS). We planned a prospective randomized clinical study. Normoandrogenemic and oligoamenorrheic women with PCOS and impaired glucose tolerance (n = 96) were enrolled in the study. Six months of treatment with metformin HCL or oral contraceptive pills (OCPs) were given to the patients. Group 1 were obese and receiving metformin. Group 2 were obese and receiving OCPs. Group 3 were nonobese and receiving metformin, and Group 4 were nonobese receiving OCPs. ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated. ADMA, homocysteine, hs-CRP and HOMA-IR were similar in obese and nonobese groups before the treatment. After 6 months of treatment, a significant decrease was observed in ADMA, homocysteine and HOMA-IR levels in Groups 1 and 3. An increase in ADMA and hs-CRP levels was observed in Groups 2 and 4. In this study, metformin treatment leads to improvement in hormonal and metabolic parameters and decreases ADMA and homocysteine levels possibly independent of BMI. However, the use of oral contraceptives in obese and nonobese patients with PCOS with impaired glucose tolerance increases ADMA and hs-CRP levels and creates an increase in the metabolic risk.


Assuntos
Anticoncepcionais Orais/uso terapêutico , Hipoglicemiantes/uso terapêutico , Metformina/uso terapêutico , Obesidade/tratamento farmacológico , Síndrome do Ovário Policístico/tratamento farmacológico , Adulto , Arginina/análogos & derivados , Arginina/sangue , Índice de Massa Corporal , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/prevenção & controle , Anticoncepcionais Orais/farmacologia , Feminino , Homocisteína/sangue , Humanos , Hipoglicemiantes/farmacologia , Resistência à Insulina , Metformina/farmacologia , Obesidade/sangue , Obesidade/complicações , Síndrome do Ovário Policístico/sangue , Síndrome do Ovário Policístico/complicações , Estudos Prospectivos , Fatores de Risco , Adulto Jovem
9.
Arch Gynecol Obstet ; 284(2): 307-11, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20811899

RESUMO

OBJECTIVE: To determine the predictive value of middle cerebral artery (MCA) to uterine artery pulsatility index (PI) ratio in preeclamptic patients. METHODS: This prospective cross-sectional study was performed on 64 preeclamptic and 131 normal pregnancies at or beyond 26 weeks of gestation between June 2007-August 2008 in the high-risk pregnancy unit of Dr. Zekai Tahir Burak Women Health Teaching and Research Hospital, Ankara. Doppler blood flow velocimetry of the uterine and umbilical arteries and fetal MCA was measured. The ratios between the PI of MCA and the mean PI value of both uterine arteries were calculated and values below the fifth percentile were considered as brain-sparing. The ratios between the PI of MCA and PI of the umbilical artery were calculated and values lower than 1.08 were considered as brain-sparing and the results were related to perinatal outcome. Statistical analysis were performed using the SPSS Software (SPSS, Chicago, IL, USA) version 9.0 for Windows. Odds ratio with 95% confidence interval (95%) was also used for statistical analysis. RESULTS: In 11 (42.3%) of the preeclamptic pregnancies that had abnormal MCA/uterine artery PI, 4 of them had severe preeclampsia and 7 had mild preeclampsia. In the low MCA/uterine artery PI ratio group, a statistically significantly higher rate of Cesarean section (66 vs. 88.46%), NICU admission (26.3 vs. 57.6%), preterm birth (52.6 vs. 92.3%) was found. Abnormal MCA/uterine artery PI ratio and abnormal MCA/umbilical artery PI ratio in the prediction of adverse outcome of pregnancy was compared. In the prediction of preterm birth, which was better for the MCA/uterine artery, there was a significant difference between the ratios (P = 0.005). CONCLUSION: Our results suggest that MCA/uterine artery PI ratio is a good predictor of neonatal outcome in preeclamptic patients in the third trimester and could be used to identify fetuses at risk of morbidity and mortality.


Assuntos
Artéria Cerebral Média/fisiopatologia , Pré-Eclâmpsia/fisiopatologia , Resultado da Gravidez , Fluxo Pulsátil/fisiologia , Ultrassonografia Pré-Natal , Artérias Umbilicais/fisiopatologia , Artéria Uterina/fisiopatologia , Adulto , Velocidade do Fluxo Sanguíneo , Cesárea , Estudos Transversais , Feminino , Feto/irrigação sanguínea , Humanos , Terapia Intensiva Neonatal , Artéria Cerebral Média/diagnóstico por imagem , Artéria Cerebral Média/embriologia , Pré-Eclâmpsia/diagnóstico por imagem , Valor Preditivo dos Testes , Gravidez , Terceiro Trimestre da Gravidez , Nascimento Prematuro , Estudos Prospectivos , Índice de Gravidade de Doença , Ultrassonografia Doppler , Artérias Umbilicais/diagnóstico por imagem , Artéria Uterina/diagnóstico por imagem , Adulto Jovem
10.
Arch Gynecol Obstet ; 283(4): 799-804, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20333392

RESUMO

OBJECTIVE: To show the efficacy of anti-tumor necrosis factor therapy (etanercept) for treating endometriosis in an experimental model. DESIGN: A randomized, placebo-controlled, blinded study using rat endometriosis model. SETTING: Experimental research center of Ankara Education and Research Hospital. ANIMAL(S): Twenty-two Wistar female rats. INTERVENTION(S): After peritoneal implantation of endometrial tissue, rats were randomized to two equal intervention groups: control and etanercept-treated groups. After measuring implant volume, blood and peritoneal fluid samples were obtained. Vehicle treatments of 2 mL saline to rats in control and 0.4 mg/kg etanercept SC once weekly were administered in treatment group. Four weeks later, a third laparotomy was performed to remeasure implant volumes, blood, and peritoneal fluid samples. MAIN OUTCOME MEASURE(S): To compare spherical volume, peritoneal fluid and serum levels of VEGF, IL-6, and TNF-α between groups. RESULT(S): There was a significant difference in spherical volume between control [131.0 (60.3-501.2)] and treatment groups [72.8 (31.2-149.6)] (p < 0.025). In etanercept-treated group, a significant difference was found between peritoneal fluid and serum levels of VEGF, IL-6, and TNF-α (p < 0.01). CONCLUSION(S): These results indicate that etanercept was found to effectively reduce the development of endometriosis.


Assuntos
Endometriose/tratamento farmacológico , Endométrio/transplante , Imunoglobulina G/uso terapêutico , Receptores do Fator de Necrose Tumoral/uso terapêutico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Animais , Modelos Animais de Doenças , Etanercepte , Feminino , Imunoglobulina G/farmacologia , Interleucina-6/análise , Distribuição Aleatória , Ratos , Ratos Wistar , Transplante Autólogo , Fator de Necrose Tumoral alfa/análise , Fator A de Crescimento do Endotélio Vascular/análise
11.
Arch Gynecol Obstet ; 283(6): 1415-21, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21562964

RESUMO

OBJECTIVE: The present study aims to compare anti-Mullerian hormone (AMH) with other ovarian reserve markers and to find a cut-off value of AMH for predicting ovarian response towards controlled ovarian hyperstimulation in an in vitro fertilization (IVF) program. MATERIALS AND METHODS: A prospective analysis was performed in 180 patients undergoing their first IVF trial, which is being conducted at a department of assisted reproduction in a tertiary medical center. The main outcome measures were determined as age and antral follicle count as well as the serum concentrations of follicle stimulating hormone, luteinizing hormone (LH), estradiol (E2), inhibin B and AMH. The predictive power of the aforementioned measures in specifying ovarian response was determined by means of discriminate analyses. RESULTS: As expected, day 3 LH levels were significantly high in the poor responder group. The poor responders had significantly lower antral follicle counts, retrieved oocyte number, and mature oocyte counts as well as day 3 AMH levels (5.8 ± 2.32 vs. 1.8 ± 0.80 ng/ml). There was a positive correlation with antral follicle count, basal AMH, E2 and follicle count on the day of HCG administration and negative correlation with age. The AMH level was addressed as the only significant factor in determination of mature oocyte number. A cut-off point for serum AMH concentration indicating the value of 2.97 ng/ml was found to predict the poor ovarian response with a sensitivity of 100.0% and a specificity of 89.6%. However, the same cut-off point was not as predictive for the non-conception circumstance. CONCLUSION: The present study concludes that AMH is a promising biochemical marker for the prediction of ovarian response and that a cut-off point indicating the value of 2.97 ng/ml can be adopted for this prediction.


Assuntos
Hormônio Antimülleriano/sangue , Endossonografia , Estradiol/sangue , Fertilização in vitro , Hormônio Foliculoestimulante/sangue , Infertilidade Feminina/terapia , Inibinas/sangue , Folículo Ovariano/diagnóstico por imagem , Indução da Ovulação , Adulto , Feminino , Humanos , Recém-Nascido , Infertilidade Feminina/diagnóstico por imagem , Síndrome do Ovário Policístico/diagnóstico por imagem , Síndrome do Ovário Policístico/terapia , Valor Preditivo dos Testes , Gravidez , Prognóstico , Estudos Prospectivos
12.
Reprod Biomed Online ; 20(2): 291-9, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20113969

RESUMO

Endometriotic implants were induced surgically in female Wistar albino rats, which were randomly divided into three groups. The rats in group I (n=10) and group II (n=9) were given 2.5 mg/kg/day intraperitoneal and oral atorvastatin, respectively, for 28 days. Group III (n=9) was given no medication (control). The mean volume and weight of explants in group I were significantly lower (both P < 0.05) compared with group III. Histopathological score of the implants was significantly lower in groups I and II, when compared with group III (P < 0.01 and P < 0.05, respectively). There were significant reductions in explant concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 in group I (P < 0.01 and P < 0.001, respectively) and group II (both P < 0.01) compared with group III while staining due to tissue inhibitor of metalloproteinase 2 was significantly higher in group I (P < 0.01) and group II (P < 0.01) compared with group III. Moreover, explant concentration of superoxide dismutase was significantly increased in groups I and II compared with group III (both P < 0.05). In conclusion, atorvastatin causes significant regression of endometriotic implants in rats. Moreover, intraperitoneal atorvastatin seems to be more effective than oral atorvastatin.


Assuntos
Antioxidantes/uso terapêutico , Endometriose/tratamento farmacológico , Ácidos Heptanoicos/uso terapêutico , Pirróis/uso terapêutico , Animais , Antioxidantes/efeitos adversos , Atorvastatina , Modelos Animais de Doenças , Endometriose/patologia , Endométrio/efeitos dos fármacos , Endométrio/patologia , Feminino , Ácidos Heptanoicos/efeitos adversos , Pirróis/efeitos adversos , Ratos , Ratos Wistar
13.
Am J Obstet Gynecol ; 202(4): 368.e1-8, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20035912

RESUMO

OBJECTIVE: We sought to test if metformin could regress endometriotic explants in rats. STUDY DESIGN: After inducing endometriotic implants and randomization of female Wistar albino rats, they were given 25 and 50 mg/kg/day of oral metformin in group A (n = 9) and B (n = 8), respectively, for 28 days. Group C (n = 9) was given saline as placebo. RESULTS: Mean volume, weight, and histologic score of implants in groups A (P < .01, P < .05, and P < .05, respectively) and B (P < .01, P < .05, and P < .05, respectively) were significantly lower than in group C. The activity of superoxide dismutase and tissue inhibitor of metalloproteinase-2 staining in groups A (P < .05 and P < .01, respectively) and B (P < .01 and P < .01, respectively) was significantly higher than in the control group. Moreover, there were more significant reductions in implant levels of vascular endothelial growth factor and matrix metalloproteinase-9 in groups A (both P < .001) and B (both P < .001) than in group C. CONCLUSION: Metformin causes regression of endometriotic implants in rats.


Assuntos
Endometriose/tratamento farmacológico , Endometriose/metabolismo , Metaloproteinase 9 da Matriz/metabolismo , Metformina/farmacologia , Superóxido Dismutase/metabolismo , Inibidor Tecidual de Metaloproteinase-2/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , Animais , Modelos Animais de Doenças , Endometriose/patologia , Endométrio/metabolismo , Endométrio/patologia , Endométrio/transplante , Feminino , Hipoglicemiantes/farmacologia , Imuno-Histoquímica , Laparotomia , Ratos , Ratos Wistar
14.
Arch Gynecol Obstet ; 282(1): 49-53, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19834722

RESUMO

PURPOSE: This study is designed to evaluate the long-term efficacy of extracorporeal magnetic innervation (ExMI) in the treatment of women with urinary incontinence. METHODS: Our prospective study included a period of 3 years between May 2005 and October 2008. A total of 137 consequent women with stress and urge incontinence were included in the study. Of the patients, 68 had stress incontinence and others had urge incontinence. RESULTS: All of the patients with stress incontinence were successfully followed up and 32 (47%) were totally dry in negative stress test at the 6 months after ExMI therapy. In the same group, 27(39%) showed improvement in the frequency of daily leak episodes from 3.2 times to 1.2 times. In the urge incontinence group, all of the patients completed the treatment and they were successfully followed up. While 40 (58%) patients were dry and 18 (26%) significantly improved the average number of incontinence episodes decreased from 3.7 times to 1.7 times per day, treatment failed in the remaining 11 (16%) patients at the 6 months. At 6 months, the recurrence rate was 53%. CONCLUSIONS: At the 6 months after 16 sessions of ExMI had a significant QOL, parallel to decrease in daily pad use and leakage episodes. Only 16 sessions are not effective definitive therapy. The beneficial effects are temporary and there is high recurrence.


Assuntos
Magnetoterapia/métodos , Bexiga Urinária/inervação , Incontinência Urinária/terapia , Urodinâmica , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Qualidade de Vida , Tempo , Resultado do Tratamento
15.
Arch Gynecol Obstet ; 281(6): 995-8, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19639329

RESUMO

OBJECTIVE: Increasing evidences support the participation of adipokines in the pathogenesis of preeclampsia (PE). Visfatin is a novel adipokine secreted by fat tissue and macrophages and is involved in the regulation of glucose homeostasis. Our aim is to investigate visfatin levels in women with PE, women with the third trimester of normal pregnancy and healthy non-pregnant women. PATIENTS AND METHODS: We included 32 preeclamptic patients who received antenatal and obstetric care at Perinatology Clinic. A total of 32 pregnant women with normal ongoing pregnancies and 32 non-pregnant women were taken as the control groups. Plasma levels of visfatin were quantified by ELISA. RESULTS: Plasma levels of visfatin were 63.8 +/- 4.9 ng/ml in women with PE, 43.6 +/- 7.8 ng/ml in pregnant control and 31.6 +/- 4.2 ng/ml in the non-pregnant control, respectively (P < 0.001). Visfatin level was significantly higher in PE compared with non-pregnant control (P < 0.001) and pregnant control (P < 0.001); also, plasma level of visfatin was significantly higher in severe PE (75.3 +/- 4.6 ng/ml) than mild PE (41.8 +/- 5.2 ng/ml) (P < 0.001). CONCLUSION: The results of the present study indicate that women with PE had significantly increased visfatin concentrations in the third trimester. Furthermore, visfatin levels were significantly higher in severe PE group.


Assuntos
Nicotinamida Fosforribosiltransferase/sangue , Pré-Eclâmpsia/sangue , Terceiro Trimestre da Gravidez/sangue , Gravidez/sangue , Adulto , Feminino , Humanos , Adulto Jovem
16.
Arch Gynecol Obstet ; 282(1): 89-96, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20091316

RESUMO

OBJECTIVE: Ovarian responsiveness to ovulation induction agents is essential for a successful clinical outcome in assisted reproductive technology (ART) cycles. We aimed to evaluate the accuracy of multinominal logistic models for the prediction of ovarian reserve and pregnancy in women undergoing ART cycles. PATIENTS AND METHODS: 1,970 patients who underwent ovarian stimulation for ART programs were evaluated. Patients were designated to ovarian response with body mass index (BMI) and age. RESULTS: When evaluating the factors affecting the egg quantity in poor responder and high responder patient groups according to the BMI, we observed that there was a lower probability of extracting less than five eggs in patients with a BMI of over 30 kg/m(2). The BMI was not an influential parameter for the amount of eggs obtained when comparing norm responder and high responder patient groups. Otherwise, obesity does not constitute a risk factor for positive pregnancy. Being 36-40 years of age is an important risk factor in foreseeing pregnancy. CONCLUSION: Predicting and managing the variability between patients is a significant clinical challenge in stimulation protocols. Research into predictive factors and the construction of multivariate models are the first steps towards evidence-based individualized treatment. The current practice of individualized treatment is based only on clinical experience and has poor reproducibility.


Assuntos
Fertilização in vitro , Obesidade/complicações , Indução da Ovulação/métodos , Taxa de Gravidez , Adulto , Distribuição por Idade , Índice de Massa Corporal , Estudos Transversais , Feminino , Humanos , Modelos Logísticos , Oócitos , Gravidez , Resultado da Gravidez , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento , Adulto Jovem
17.
Arch Gynecol Obstet ; 281(6): 1051-9, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20084388

RESUMO

Progestin-only (p-only) contraceptives often cause breakthrough bleeding for unknown reasons. In this study, we aimed to evaluate the long-term effects of p-only contraceptives to gain a better understanding of breakthrough bleeding mechanism. Wistar rats were divided into etonorgesterel implant (Group 1, n = 25), depot medroxyprogesterone acetate injectable (Group 2, n = 25), and control groups (n = 5). Five rats each from groups 1 and 2 were examined every 10 days for up to 50 days after the medication. Uteri and ovaries were removed and prepared for immunohistochemistry and scanning electron microscopy. The tissue nitric oxide (NO) levels were determined by Griess reaction. Dynamic changes of endometrial estrogen and progesterone receptor immunoreactivity were observed in a time-dependent manner in groups 1 and 2. The number of endometrial pinopodes, which are small endometrial protrusions, increased in both groups. There was no difference between groups for the estrogen receptor in the surface epithelium of the ovary. Estrogen-alpha and progesterone receptor in follicular cells decreased in a time-dependent manner. The granulosa cells underwent atrophic and were disorganized. Decreased levels of uterine tissue NO were determined in groups 1 and 2. The effect of some p-only contraceptives make some dynamic changes in the endometrium, ovaries, steroid hormone receptors, cell morphology, and biochemical features of the tissues during their use.


Assuntos
Anticoncepcionais Femininos/farmacologia , Desogestrel/farmacologia , Endométrio/efeitos dos fármacos , Acetato de Medroxiprogesterona/farmacologia , Ovário/efeitos dos fármacos , Progesterona/farmacologia , Animais , Preparações de Ação Retardada , Modelos Animais de Doenças , Feminino , Ratos , Ratos Wistar , Fatores de Tempo , Hemorragia Uterina/etiologia
18.
Acta Histochem ; 122(1): 151465, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31776004

RESUMO

Asherman's syndrome has become a growing problem with the incidence of cesarean and endometrial surgical procedures. A surgical procedure that can damage to the basal layer of the endometrium is formed as intrauterine adhesion and can cause asherman's syndrome. Mesenchymal stem cells (MSCs) are characterized by some characteristics such as non-immunogenic, angiogenic, antifibrotic, antiapoptotic and antiinflammatory properties, also they support tissue repair by secretion of various factors and chemokines in cellular therapy. Exosomes are active paracrine components with a great potential for repairing damaged tissue. Exosomes include many paracrine factors responsible for regeneration and angiogenesis. In this study, 10 newborn Wistar rats were used to obtain MSCs. A total of 24 adult Wistar rats were also used. The rats were divided into 4 groups: untreated control group; asherman control group; asherman + uterine-derived MSCs group; asherman + uterine-derived MSCs-exosomes group. At the end of the experiment, uterine tissues were evaluated by histochemical and immunohistochemical. As a result of MSCs and exosomes treatments, proliferation and vascularization in uterine tissue was increased. It was also shown to reduce fibrosis with masson's trichrome staining. MMP-2 and MMP-9 expression was enhanced by MSC and exosomal therapy; in addition, TIMP-2 expression was decreased. In our study, it was shown that proliferation and vascularization increased and fibrosis decreased in uterus as a result of MSC and exosome treatments. Our results indicate that the exosomal treatment restored the damage of asherman's syndrome at tissue at a shorter time than the MSCs group.


Assuntos
Exossomos , Regulação da Expressão Gênica , Ginatresia , Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais , Útero , Aloenxertos , Animais , Exossomos/metabolismo , Exossomos/patologia , Exossomos/transplante , Feminino , Ginatresia/metabolismo , Ginatresia/patologia , Ginatresia/terapia , Células-Tronco Mesenquimais/metabolismo , Células-Tronco Mesenquimais/patologia , Ratos , Ratos Wistar , Útero/metabolismo , Útero/patologia
19.
Gynecol Obstet Invest ; 68(4): 234-8, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19776610

RESUMO

OBJECTIVE: Premature labor is still the leading cause of infant mortality and morbidity worldwide. Multiple etiological factors including genetics and environment are held responsible for preterm birth. However, scientific data regarding the link between premature birth and genetics are limited. SUBJECTS AND METHODS: In this study, we included 50 women who had premature labor (group 1) but did not have any known risks for a premature delivery such as uterine anomaly, polyhydramnios, hypertension, and diabetes mellitus, and another 50 healthy women who had term labor as control (group 2). We compared these two patient groups for MTHFR C677T, MTHFR C1298T, prothrombin 20210A, factor V and ACE polymorphisms. RESULTS: We could not detect a statistical significance between groups for polymorphisms in MTHFR C677T, MTHFR C1298T, prothrombin 20210A, factor V and ACE polymorphisms. CONCLUSION: We investigated the relationship between premature and term labor and thrombophilic gene polymorphism. However, we found no associations with premature or term labor with the parameters included.


Assuntos
Trabalho de Parto Prematuro/genética , Polimorfismo Genético/genética , Trombofilia/genética , Adolescente , Adulto , Estudos de Coortes , Fator V/genética , Feminino , Humanos , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Peptidil Dipeptidase A/genética , Gravidez , Estudos Prospectivos , Protrombina/genética
20.
J Assist Reprod Genet ; 26(1): 57-63, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19107589

RESUMO

PURPOSE: To investigate immunostaining pattern of caspase-3, an apoptosis marker, and vascular endothelial growth factor (VEGF), an hypoxia marker in testis biopsy specimens collected either from smoking or non-smoking patients with azoospermia. METHODS: Testis biopsy specimens were obtained from thirty seven non-smoker and thirty eight smoker patients. Using immunochemistry technique, caspase-3 and VEGF were evaluated in all intratubular spermatogenic and interstitial Leydig cells. RESULT(S): Caspase-3 expression was significantly increased in germ cells in maturation arrest specimens in smoker azoospermic patients. No statistically significant difference was present between smokers and non-smokers for caspase-3 expression in Sertoli cell. However, the VEGF immunopositive Leydig cells were statistically higher in smokers. There were no differences between groups in terms of germ cell immunopositivity. CONCLUSION: Our results support the hypothesis that increased apoptosis contributes significantly to impaired spermatogenesis. We conjecture that germ cell apoptosis may be augmented by hypoxic microenvironments and environmental toxicants in smoking azoospermic men.


Assuntos
Azoospermia/metabolismo , Caspase 3/metabolismo , Túbulos Seminíferos/metabolismo , Fumar/metabolismo , Espermatozoides/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , Adulto , Apoptose , Azoospermia/patologia , Azoospermia/psicologia , Humanos , Imuno-Histoquímica , Células Intersticiais do Testículo/metabolismo , Células Intersticiais do Testículo/patologia , Masculino , Pessoa de Meia-Idade , Túbulos Seminíferos/patologia , Células de Sertoli/metabolismo , Células de Sertoli/patologia , Fumar/patologia , Espermatogênese , Espermatozoides/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA